Prognostic role of Interleukin-6/lymphocytes ratio in SARS-CoV2 related pneumonia
SARS-CoV2 관련 폐렴에서 인터루킨-6/림프구 비율의 예후 역할
Article
Published on
Journal: International immunopharmacology [Category] COVID19(2023년), MERS, SARS, 바이오마커,
Journal: International immunopharmacology [Category] COVID19(2023년), MERS, SARS, 바이오마커,
[키워드] 95% CI
Admission
age
analyzed
AUC
Biomarker
C-reactive protein
collected
COVID-19
COVID-19 patient
CRP
cytokine
Cytokine storm
D-dimer
defined
died
dimer
discharged
Endpoint
females
fibrinogen
High flow nasal cannula
highest
Hospital admission
Hospital mortality
Hospital stay
ICU
IL-6
in-hospital mortality
independent
Intensive
intensive care unit
interleukin
interleukin-6
intubation
invasive ventilation
lymphocyte
Lymphocytes
material
mean value
Mortality
multivariate
multivariate logistic regression
N/L
nasal
nasal cannula
neutrophil
no difference
outcome
Patient
Pneumonia
Prognosis
prognostic
required
Respiratory failure
SARS-CoV2
severe respiratory failure
significantly higher
significantly lower
study population
suffered
tested
[DOI] 10.1016/j.intimp.2021.108435 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.intimp.2021.108435 PMC 바로가기 [Article Type] Article